C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/435 (2006.01) A61K 38/17 (2006.01) A61K 39/00 (2006.01) C07K 16/18 (2006.01) C12N 1/21 (2006.01) C12N 15/12 (2006.01) C12N 15/63 (2006.01)
Patent
CA 2397731
The invention relates to a recombinant polypeptide that comprises the N- terminal region of .alpha.-Latrotoxin, is capable of generating an immune response in mammals and efficiently and fully neutralizes the venom of the black widow spider. The invention also relates to the cDNA coding for said polypeptide, the vector for the expression thereof, the bacterial cells transformed into said vector and the method for producing the polypeptide by means of cultivation of said cells. The invention further relates to the use of said recombinant polypeptide as a vaccine against the poison of the black widow spider and to the pharmaceutically acceptable preparations of said vaccine. The invention additionally relates to the use of said recombinant polypeptide as immunogen for generating antivenom serum for the black widow spider, obtaining serotherapeutic agents by serum purification and fab therapeutic agents by enzymatic hydrolysis of the antibodies of the serum. The invention also relates to an immunogen matrix that is useful in the separation and purification of antibodies and the specific fragments thereof against the venom of the black widow spider.
L'invention concerne un polypeptide recombinant contenant une région à N terminaison de la .alpha.-Latrotoxine et capable de générer une réponse immunitaire chez les mammifères, efficace pour neutraliser complètement le venin de l'araignée veuve noire. L'invention concerne également l'ADNc codant pour ce polypeptide, le vecteur pour son expression, les cellules bactériennes transformées par ledit vecteur et le procédé de production du polypeptide par le biais de la culture de ces cellules. L'invention concerne, sur un autre tableau, l'utilisation du polypeptide recombinant comme vaccin contre le venin de la veuve noire et les préparations pharmaceutiquement acceptables du vaccin, ainsi que l'utilisation du polypeptide recombinant comme immunogène pour la génération de sérums anti-venin de la veuve noire, l'obtention d'agents de sérothérapie par purification du sérum et l'obtention d'agents de thérapie FAB par hydrolyse enzymatique des anticorps du sérum. L'invention concerne finalement une matrice immunogène utile dans la séparation et la purification d'anticorps et ses fragments spécifiques agissant contre le venin de la veuve noire.
Alagon Cano Alejandro
Grishin Eugene Vasilevich
Gurrola Briones Georgina
Lipkin Alexei Valerevich
Possani Postay Lourival Domingos
Mbm Intellectual Property Law Llp
Shemyakin And Ovchinnikov Institute Of Bioorganic Chemistry
Universidad Nacional Autonoma de Mexico
LandOfFree
Immunogen antivenom and vaccine against the venom of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogen antivenom and vaccine against the venom of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogen antivenom and vaccine against the venom of the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1844342